Blog

  • Daily U-Turn: What you missed on 11.24.09

    Review: 2009 Infiniti G37X Sport makes no excuses

    The Infiniti G series relied on its lower cost of entry to make up for its shortcomings. With the G37X Sport, that’s no longer the case.

    Quick Spin: Nissan Leaf the tip of mass market EV spear

    We take the Nissan Leaf all-electric vehicle for a spin in So. Cal. to see if one mainstream automaker is finally ready to bring EVs to the masses.

    Daily U-Turn: What you missed on 11.24.09 originally appeared on Autoblog on Tue, 24 Nov 2009 19:20:00 EST. Please see our terms for use of feeds.

    Permalink | Email this | Comments

  • Protexid and Protexid ND and adventures in DR

    I’m going to reveal the only medical problem I have (at least that I know of) other than the propensity toward obesity when I eat too many carbs.  I’m going to explain how the direct response business works.  I’m going to talk about the problems direct marketers have in dealing with our servants in Washington. And I’m going to tell you how you can get the best nutritional supplement I’ve ever seen in action absolutely free.  How’s that for a pleiotropic post?

    First the medical problem.  I’ll reveal it in true AA fashion.

    I am a GERD (gastroesophageal reflux disorder) sufferer.

    I don’t get it often, but when I do, it’s a nightmare.   As long as I stick with my own diet, I never ever have a problem.   But sometimes, what with traveling and all, I’ll stray from the straight and narrow for a bit.   The first day or two or even three after I’ve fallen off the wagon, I don’t have symptoms.  But starting about day three or four, it turns brutal.   And like most everyone else, once the let’s-eat-carbs devil is on me, I want to keep on going.   And I pay dearly.   I actually become afraid to go to bed because I know what’s going to happen.   Those of you who are fellow sufferers know what I mean.

    I’ve taken to never going far without my team of GERD-preventative products, which, even though OTC, are really the only semi-sort of medicines I ever take.   I always packed the duo shown below: Tums and Pepcid AC.   Both are OTC, although Pepcid used to be prescription.   I hated to take them, but I hated the symptoms of GERD even worse.

    GERD regimen1

    Now for the direct response business.

    A direct response company (DR) is one that sells products direct to consumer through channels other than retail stores.   Companies that sell through catalogs, online, direct mail, infomercials, Google ads, websites, etc are called DR companies.   Anyone who sells this way is said to be in DR sales.   Many companies have physical stores but still have a DR arm that sells through catalogs and online.   The little product section of our website is a DR store.

    As I’ve mentioned on this blog, or at least in the comments somewhere, MD and I are part owners of a couple of DR companies that produce and sell unique, patented nutritional products.   I’ve avoided promoting any of those products on this blog because I didn’t want to contaminate it with commercial marketing. I want what I write to be accepted as my opinion based on my years of practice and my reading and understanding of the medical literature, not as an overt or even subtle effort to drive readers to buy products that I may have to sell.  Any time I do post about a product, which I did once with Pentabosol, I am always clear that I am in the business of selling said product, and I expect anyone reading what I have to say about it as coming from someone who stands to gain financially by its sales.

    I will never follow the loathsome practice used by a majority of the newsletters out there that recommend products in a seemingly unbiased fashion then offer a link for readers to purchase those products from what appears to be a third party, but which, in reality, is a company owned by the newsletter publisher.  I believe such behavior is beneath contempt.

    How does my GERD and my involvement in the DR business all come together in one post?

    Because GERD is a problem that afflicts me, I do a fair amount of research on it.   Through this research, I’ve discovered that I’m far from alone in suffering GERD’s debilitating effects.  There are estimated to be anywhere from 25 million to 40 million fellow GERD sufferers in the US alone, numbers that get the attention of the DR marketer in me. (Not to mention the pharmaceutical companies, which is why the commercials for the little purple pill are all over TV.) For several years, I’ve been on the lookout for a natural supplement that works for GERD. If you google GERD or heartburn, you’ll find plenty of nutritional supplements, but based on my experience, none of them really work – at least not for me.  Below is a photo I took of a part of an entire section at Costco devoted to OTC reflux meds.

    Costco gerd1

    A few years ago I was doing my morning cruise through the medical literature when I came upon a paper by a Brazilian scientist about a natural supplement he had developed and used successfully to treat severe GERD. I read his paper his paper (pdf file) and found a follow-up paper and was intrigued. He had compared his supplement head to head with omeprazole, the generic for the drug Prilosec (and the precursor to Nexium, the little purple pill), and his supplement had won.   Moreover, he had a large number of subjects – almost 300, which is a pretty huge number for trials with natural supplements.  Usually it’s something in the range of 10-20.  He found that within 40 days ALL the subjects on his supplement had achieved complete relief from their GERD symptoms whereas only 67 percent of those on the drug had done so.  As you might imagine, this paper got my attention.

    When I looked at the ingredients, it didn’t look to me as if they would particularly work to relieve GERD, but, according to his study, not only did they work, they were shown by endoscopy to actually heal ulcerations.  The follow-up paper (pdf file) had photos of the healing progression.  In doing further research on the product and the ingredients, it looked as if this product worked in a different way than all the others on the market.

    Since the beginning, when people first starting treating GERD and acid reflux, they’ve used a variation of the same treatment: reducing the amount of stomach acid.  The theory is that acid from the stomach gets through a loosened lower esophageal sphincter (LES), the muscular ring that holds the bottom of the esophagus closed, and splashes onto the delicate tissues of the esophageal lining, burning them in the process.  Although new theories are emerging as to what really causes GERD, the excess acid reflux theory has held sway for ages.  According to the precepts of this theory, if you can reduce the degree of acidity of the stomach acid or cause the stomach to produce less of it, you can reduce the effects of the acid that makes its way through the LES to the vulnerable esophageal cells.

    Antacids, the earliest approach developed, work by neutralizing stomach acid.  The newer drugs such as Prilosec and Nexium work by making the stomach produce less acid.  In both cases, the problem is solved by either getting rid of the acid or neutralizing it.  Which, for the most part, works to reduce or eliminate the symptoms of GERD.  But, and this is a big ‘but,’ maybe isn’t the best way to go.  Stomach acid is there in the stomach for a reason.

    It’s the first line of defense against microbe invasion.  If you swallow germs, the acid works to destroy them.  When you breath in germs, they get stuck to the mucus in your respiratory tract, then the little hairs (that haven’t been burned off due to smoking) move this mucus, filled with germs and particulate matter you don’t want in your lungs, upward and dumps it in the back of your throat (you never notice this happening, but it happens 24 hours per day) from where you swallow it.  Those bugs then get killed when they hit the acid in the stomach.

    When food reaches the stomach, the stomach acid acts upon it as the first phase of the digestive process.  Protein starts to be broken down in the stomach.  When the acidic stomach contents are released into the first part of the small intestine, their acidity stimulates the release of alkaline juices to neutralize them and do other work in the digestive process.  Whenever stomach acid is gotten rid of or neutralized, the very first step in the digestive process is compromised and there is a domino effect from there on.

    Studies are starting to demonstrate that those who take the newer anti-GERD drugs suffer a higher incidence of pneumonias and other infections (which makes sense since the first line of defense is knocked out) and more osteoporosis and hip fractures (which also makes sense since protein digestion and absorption is affected).  As far as I know, antacids haven’t been implicated, but that’s probably because people don’t take them all the time as they do these other drugs.  Most people only take antacids as they need them, so their acid isn’t affected 24 hours per day, day in and day out.

    This Brazilian product appeared to work by strengthening the LES so that the acid didn’t get to where it wasn’t supposed to be.  But the acid itself wasn’t effected, so the digestive process could perform unhindered.

    I thought this could be a terrific product for DR, so I tracked the researcher down in Brazil.   He told me he had used the supplement on many, many patients besides the ones in the study and that he was shipping it all over Brazil and to people in the US and Canada.  Furthermore, he informed me that he had the worldwide patent rights on the product.   I told him I would love to work an arrangement with him to get the exclusive license to make and sell his product.  I (and my partners) flew him to the US where we put him up for a week and picked his brain on the product.  Satisfied that it was legit and that his patents were in order, we executed a worldwide exclusive licensing agreement with him.

    We began to formulate a strategy to sell the product, which we named Protexid.   We decided to start with a radio infomercial because they are much less expensive to produce and can be used to work out the bugs in the presentation before jumping into the much more expensive television infomercial market.   At the same time we were in the planning stages for the radio infomercial we were working to come up with a name for the product (the name he was using in Brazil wouldn’t make any sense to an American consumer), designing the labels and accompanying literature and all the rest of the creative stuff that has to be done to bring a product to market.

    Our Brazilian doctor had sent us names of clients he had in the US who had been using his product.  We got in contact with a number of these folks and found them to have been tremendously satisfied and several were willing to be testimonials for us.  Once we had all the parts of the promotion together, MD and I went to a studio and recorded the radio infomercial.  We stayed in the booth for two days making a number of iterations of the program.  Once finished we got the shows transcribed and sent the scripts to the attorney whose job it is to keep us out of trouble with all the government regulatory agencies.   MD and I are old hands at this, so we pretty much know how to do these things on the fly and stay in the clear.  Consequently, we were expecting a few little cuts here and there, but nothing that would substantively alter what we were trying to say.   We’re we ever in for an eye opener.

    Here comes the part about our friends in Washington.

    When we spoke with the lawyer, we found that our show had been cut to the bone.   GERD is a disease, and if you make disease claims – as in, it relieves the symptoms of GERD – you are making a disease treatment claim, which runs you afoul of the FDA.   The only way you can make a so-called disease claim is to go through the same kind of extensive FDA-approved studies as drugs have to go through.   If you try to make a disease claim without doing this, you get hammered by the FDA.   Then there are all the FTC regs.   About half the time you can’t say one thing because the FDA won’t let you and the other half you can’t something else because the FTC won’t let you.   After our lawyer – who really is reasonable – got through with our show, it turned out that the only claim we could actually make was the following:  Protexid may offer relief from occasional heartburn.   Nothing about GERD, nothing about acid reflux, nothing about the long term problems with untreated GERD, and nothing about how our product stacked up against a prescription drug.   All in all, our program had been totally emasculated.

    We had no way to explain how phenomenal Protexid really is without risking serious problems from our government watchdogs.  Which is extremely frustrating when you’ve got a product that works as well as this one and that so many people could benefit from.

    And it works extremely well.

    As we were fiddling with all the work necessary to get this project moving, I was going about my business doing all the things I normally do including tending to this blog.   Over the first couple of months or so that we had the product I had an episode or two of GERD, but dealt with them with Tums and Pepcid AC as usual.   I didn’t use our own product for a couple of reasons.   First, the samples we had gotten from the Brazilian doc had been made in China and I wasn’t about to take them.  Second, when I got GERD, I got it bad (for some reason, I never have a slight case or a touch of it; I always have the full-blown version), and I wanted to take something I knew worked, not something I had never taken before.  So even when we had our own US manufactured product, I didn’t take it myself.

    I’ve had tons of experience with natural supplements, and they all pretty much work the same.   You take them for several weeks or a few months and you build up levels that actually start to work.  Krill oil had been the perfect example.   I took a krill oil/fish oil/curcumin combination to relieve my aches and pains from playing too much golf so I could quit taking all the ibuprofen I was taking.  After about a month and a half I was pretty much ache and pain free.   Now I take only a single krill oil softgel and one curcumin daily to keep myself that way.  But it initially took almost two months for the natural supplement combo I was using to kick in and do its thing.   Which, in my experience, is pretty much the standard course with natural supplements: many work, and work well, but it takes time.

    When I have an episode of GERD, I don’t have time to wait.   I want relief now.   I don’t want to lay awake all night in agony and do so for two months while I’m waiting for the natural supplement to kick in.  Thus I never used our own product the couple of times I needed something.

    Until one time MD and I went on a several-day-long trip, and I forgot to take my Tums and Pepcid.  A couple of days into the trip, I could tell I was going to get GERD that night. (Most of the time I can tell when it’s going to happen; occasionally it sneaks up on me.)   I was desperate.   I was getting ready to head off to find a drug store and get the stuff I needed, but MD brow beat me into taking a Protexid.  I took one capsule (the standard dose) at bedtime and experienced no GERD.  I wrote it off as a fluke.  But then I tried it again the next night and, again, no symptoms. I tried to test it by eating a bunch of junk that I knew would normally do me in.  One capsule at bedtime and nothing.   This is what the Brazilian doctor had told me, but I simply hadn’t believed him.  Once I saw how well it worked for me, I became almost a religious convert.  I knew a few guys I played golf with who had GERD.  Most took prescription drugs daily for the condition.   I got them to try the product.  In every case, they got complete relief with one capsule at bedtime. I was stunned that it worked so well.

    I have had probably 30 people that I now know first hand who have taken this product with success equal to mine.   One guy – a surgeon – ditched drugs he had been taking for years and got total relief.   He feared he was going to have GERD one night, and so took one of his prescription drugs that night in addition to the product.   He didn’t have symptoms and we don’t know if he would have on the product alone or not.   But that’s as close as we’ve come to a treatment failure with his product.

    In fact, in all my years of medical practice, I have never seen a natural supplement that works like this one.   It works quickly and it takes only one capsule at bedtime, not the large doses throughout the day that are associated with most natural supplements.   It is the only supplement I’ve ever seen that has truly drug-like effects in terms of speed of action and efficacy.

    So we’ve got this great product and we can’t really tell people via paid advertising how it really works.  We ran our emasculated radio infomercial, but, as expected, it didn’t do squat.  The people who purchased the product were happy, but not nearly enough bought it to make continuing to run the show profitable.  We cut our losses and shut down.

    We were approached by another company that wanted to promote our product via television infomercial, so we negotiated a sub-licensing agreement with that company.   This outfit went over the moon in making claims about Protexid (in our licensing agreement, of course, we made sure we were exempt from any liability for claims this company made), yet they, too, were unsuccessful in making the promotion a success.  They spent even more money and tried again with even more aggressive claims and got very little return.  They finally gave up and returned the rights back to us.

    Why didn’t these shows work?  We knew ours didn’t work because we couldn’t really describe how effective the product really is.  But how about the other show?  The one that took it over the moon in terms of claims?  Why didn’t it sell there? I’ve got my suspicions as to why that I’ll talk about it a bit.

    Right now we’re scratching our heads about what to do with this phenomenal product. I put it up on the catalog part of our website, but no one really knows what it is, so we haven’t really sold much Protexid that way.

    Which brings me to the point of this meandering post.  We’ve worked on this project for going on three years now and the Protexid we’ve got left is going to expire soon.  It really isn’t going to expire in terms of efficacy, but it’s going to expire based on the dates the manufacturer printed on the bottles.

    There are two versions.  The first, pictured to the right, is the original that is the product used in the published study.  It’s in a blue bottle and is called Protexid. (In case you’re wondering, Triparadol is what the name is in Brazil) The other is in an orange bottle and is called Protexid ND.  The Protexid ND has lower doses of a couple of ingredients and seems to work as well as the regular strength product.  I’ve used both – I use whichever I happen to have at hand when I need it – and haven’t seen a difference.  The Brazilian doctor uses the lower dose all the time and in his follow-up paper he used the lower dose, but we made the higher dose so we thought we could use the first paper that compared Protexid to the prescription drug.  Had we used the first published paper to support the claims for the product with the lesser dosage, we would have been hammered.

    We have about 80 of so bottles of the blue, full-strength Protexid, but it expires at the end of November.  We have more bottles of the Protexid ND, which expires at the end of December 2009.  I don’t know off hand how many Protexid ND we have, but substantially more than the other.  As I say, as far as I can tell, they both work the same.

    Get it free!

    Anyone who wants to try this product can get it absolutely free by ordering on our website.  The price should be set at $0.  All you will have to pay is the shipping and handling, which is minimal.  Please, though, no more than two per person.  That’s TWO per person.  It can be one of each or two of one kind, but not two of both kinds.  I want to make sure that everyone who wants to try Protexid gets a chance, and there really is a limited amount left.  No obligations on your part.  You don’t have to sign up for more.  Just grab it and run.  So, if you or someone you know has the problem, give it a try.

    I don’t think Protexid will ever be a good infomercial product because due to government regulations it can’t be promoted in a way that explains what its real benefits are.  And without the explanation no one really wants to purchase a product that ‘may offer relief from occasional heartburn.’  And the obvious problem with GERD is that it hurts and that some people actually spit up acid and burn their throats.  These problems can be solved with prescription medicines – or, as in my case, with OTC meds.  But without the explanation as to why these aren’t the best solutions, why would anyone have the impetus to pay for Protexid when prescription drugs that relieve the symptoms can be had for the price of a co-pay.

    So we are changing course to look at selling Protexid into the retail market and/or through health practitioner’s offices. I have a friend who is a naturopathic physician who works in an integrative pharmacy, which is one that does compounding and sells a lot of nutritional supplements along with prescription medicines.  She tells me that almost 70 percent of people who come into the pharmacy (who aren’t coming in specifically to get a prescription filled) are looking for something for GI problems, and that most of those are having problems with GERD.  The pharmacy in which she works is in an upscale part of Los Angeles, and she says most of the people coming in have a prescription for Nexium or one of the other similar drugs, but are looking for natural alternatives.  This is the group we need to be marketing Protexid to, but our whole team are skilled only in the DR way of marketing.  None of us have a clue as to how to get a product into a pharmacy.  I’m constantly amazed at the collective wisdom of people who read this blog.  Maybe someone out there is experienced in retail placement or other means of distribution that they could direct me to.  If so, I would love to hear from you.

    And if anyone has used this Protexid ( you know who you are) and wants to tell about the experience – good or bad – send it to the comments, and I’ll post for all to read.

    Until we get our marketing strategy worked out, we’re probably not going to manufacture any more Protexid, so gets yours free while they last.

    One last thing.  I’ve given Kristi, our long suffering assistant who works for slave wages, time off for good behavior, so she is leaving tomorrow for Thanksgiving with relatives.  She may not be able to get some of these orders out until Monday.  Thanks in advance for your patience.

  • Autoblog Podcast #154

    Filed under: , , , , , , , , , ,


    Click above for the Autoblog Podcast in iTunes, RSS or listen now!

    Episode #154 of the Autoblog Podcast is here for your tryptophan-addled pleasure. Chris, Sam, and Dan kick it, starting with the BMW 5 Series, then move on to such appetite supressants as the Lexus GX, Acura ZDX and its pricing, and Infiniti’s re-style of the massive QX56 rig. Before we become an emetic, we move on to the pretty new Infiniti M, the ongoing anticipation for a US-bound Chevrolet Spark, and Hyundai’s new 2.4 liter direct-injection 4 cylinder for the next Sonata. We hit some questions, and wrap it up in time for pie.

    If you’re looking to bulk up on podcast excellence over the Thanksgiving holiday, check out our colleagues at Joystiq and Engadget. Let us know what you think by dropping us an email at Podcast at Autoblog dot com, reviewing the show in iTunes, filling out our survey, or even leaving us a voicemail on our Google Voice line 734-288-8POD (734-288-8763). Thanks for listening, we’ll see you next week!

    Continue reading Autoblog Podcast #154

    Autoblog Podcast #154 originally appeared on Autoblog on Tue, 24 Nov 2009 19:10:00 EST. Please see our terms for use of feeds.

    Read | Permalink | Email this | Comments

  • Hacker Puts Mac OS X On Sony VAIO X


    mac-vaio-x

    Ever heard of a hackintosh? If not, it’s essentially someone loading OS X on non-Mac hardware. According to some pictures that have surfaced on Facebook, a Chinese hacker was able to put OS X on the Sony VAIO X. This is rather amusing because the notebook already has been compared to the Macbook Air due to their similarities. I’m not sure how well the VAIO X handles OS X, but with up to 2GB of RAM and a speedy SSD I can imagine that the experience is probably pleasing. It’s a shame that Apple doesn’t let other hardware manufacturers build systems with its operating system, as I’m sure there are consumers out there who would probably enjoy the option of buying something like this as standard.

    mac-vaio-x-2

    Thanks, GadgetMix.

  • Audi RS6 Avant driver reportedly caught going 133 MPH with nearly 2,000 pounds of pot

    Filed under: , , , , ,

    Audi RS6 Avant – Click above to for high-res image gallery

    If you read publications about cars long enough, you’ll no doubt catch on to our pro-wagon bias. In fact, if us auto-journo types ran things, SUVs, CUVs and sedans would be banned, and all passenger cars would either be mid-engined, 500 horsepower coupes or 600 hp wagons. With manuals and roll up windows. No, really. This is the type of thinking required to join our vaunted profession. However, one of the many reasons we want mega-burly wagons isn’t to haul one ton of dope around.

    Seems that a twin-turbo, Lambo-V10 engined Audi RS6 Avant (good for at least 580 hp) was busted outside of Seville, Spain for not only going 133 mph, but for carrying 2,000 pounds of pot. Twenty-seven bundles of hashish to be specific. Value? €120,000, or about $180,000 USD. That’s a lot of grass, man. And probably about one thousand pounds more than a RS6 sedan could have carried. Er… umm… we mean…. “Bad RS6 Avant, bad!”

    [Source: Motor Pasion]

    Audi RS6 Avant driver reportedly caught going 133 MPH with nearly 2,000 pounds of pot originally appeared on Autoblog on Tue, 24 Nov 2009 18:56:00 EST. Please see our terms for use of feeds.

    Permalink | Email this | Comments

  • UK Prisoners Go on Holiday

    As prisoners in the United Kingdom near the end of their sentences, they are sometimes eligible to leave prison for a week or more at a stretch to perform community service and begin the process of reconnecting to their families and communities. The program isn’t new, but it’s drawing fresh criticism because its use has tripled in the last three years.

    This holiday, however, doesn’t look much like the photo at left.

    The program isn’t markedly different from house arrest or conditional parole — prisoners often perform community service or stay with family under strict rules. Critics of the program are stuck in a world of long sentences set in stone, and that’s a mistake.

    Programs like this should be available to prison administrators to offer reentry prisoners opportunities to transition successfully back to society. It must be carefully targeted at prisoners who deserve the privilege, however, and it should also be accompanied by state services, as we’ve seen that the first 48 hours are critical to a successful reentry.

    (more…)

  • Amazon Kindle 2: Now with PDF support, 85% more battery life

    Amazon Kindle 2

    In what we are guessing is an attempt to make the a bit more attractive when compared to the B&N , Amazon announced today that the Kindle 2 now ships with PDF support and a battery that lasts almost twice as long as previous Kindle 2s. The battery bump, in particular, gives you 7 days of use with wireless on as opposed to 4.

    Even cooler, though, is the fact that if you already own a Kindle 2, there will be a firmware update released over-the-air that will give you the same functionality, including the 85% increase in battery life! No date has been announced for the release of that update, but we’d be surprised if it didn’t arrive any day now. Gotta love competition. You can pick up the Kindle 2 on Amazon.


    Tags:
    ,
    ,
    ,
    ,
    ,
    ,
    ,
    ,
    ,
    ,
    ,

    Amazon Kindle 2: Now with PDF support, 85% more battery life originally appeared on Gear Live on Tue, November 24, 2009 – 3:41:02


  • NHTSA opening probe into Ford Freestar/Mercury Monterey transmission defect

    Filed under: , , , ,

    The National Highway Traffic Safety Administration (NHTSA) is investigating hundreds of reports that 2004-2005 Ford Freestar and Mercury Monterey minivans are fitted with defective transmissions that could dangerously fail without warning. Most alarming is that many of the transmissions reportedly fail at highway speeds. In a common complaint, the engine will suddenly surge and then all power is immediately lost. The vehicle is forced to coast powerlessly to a safe spot out of the flow of traffic. Angry owners have flooded message boards to report incidents of transmission failures which leave them stranded and stuck with $3,500 repair bills.

    To date, there have been 654 customer complaints and 2,791 warranty claims. However, according to NHTSA, as many as 205,000 vehicles may be affected. The investigation, expected to take a year, will focus on the torque converter output shaft which drives the wheels. Ford Motor Co. has not yet released an official statement regarding the investigation.

    [Source: Automotive News, subs. req’d]

    NHTSA opening probe into Ford Freestar/Mercury Monterey transmission defect originally appeared on Autoblog on Tue, 24 Nov 2009 18:31:00 EST. Please see our terms for use of feeds.

    Permalink | Email this | Comments

  • EFF Launches New “Terms of (Ab)Use” Page

    One cannot go online today without eventually being asked to accept a set of so-called Terms of Service (or TOS). Such TOS agreements have become ubiquitous to websites and other online services in the same way End User License Agreements (EULAs) have become the mainstay of the software industry. Yet while we are often aware that such Terms of Service exist, very few of us know and understand what they actually say.

    The time has come to shed light on what these Terms of Service agreements contain, and what it means for users. In conjunction with our TOSBack project, EFF is proud to announce Terms of (Ab)Use: a source for news and updates on TOS issues around the Web. We also will be periodically publishing a series of white papers that will provide the average Internet user a general background on many of the legal issues that surround Terms of Service agreements.

  • Comparing File Sharing To Payola: Could Have Had That Promotion For Free

    BullJustin points us to a short NPR piece about four massive failures by the recording industry. If we skip over number 3 (Kevin Federline), the other three are pretty relevant to what we talk about here on a regular basis: the Sony BMG rootkit fiasco that opened up security holes on computers without letting anyone know, the RIAA’s lawsuit strategy of suing fans and the record labels’ ongoing efforts at payola to get songs played on the radio.

    However, BullJustin makes an amusing point in the submission concerning that last one:


    It cost the industry untold millions in actual payola, independent promoter fees, and then more than $25 million in settlements, not to mention lawyer fees. If they would have just let people share the music online, the marketing they were looking for could have been free.”

    It really does make you wonder what goes through the minds of record label strategists. They tossed away millions paying people to get music heard, when they could have just embraced file sharing and made it cheaper and easier to get music heard without running into the legal problems of payola as well. Of course, the problem with that plan is that the labels also lose “control.” They’ve paid to get songs on the radio because they wanted to just focus on a small group of artists who they could squeeze for as much profit as possible, dumping all the rest. File sharing makes it harder and raises the possibility that other artists might also get heard.

    Permalink | Comments | Email This Story





  • Sony Ericsson Satio Withdrawn From Two Major UK Retailers Over “Software Problems”


    SE0809_satio_hero_black_scr

    According to a recent Reuters article, UK retailers Carphone Warehouse and Phones 4U have withdrawn the Sony Ericsson Satio from general availability after numerous customers reported “software problems.” Whilst there aren’t any specific details of the errors, BBC News is reporting that it is related to “frozen screens and problems with ringtones.” This is rather depressing news for Sony Ericsson, who has had a very turbulent experience in the mobile market in the last few years with massive losses in market share. Sony Ericsson has offered one of its strongest hardware lineups in recent memory with the Satio, Aino, and Yari, which excited many consumers because of their interesting features. However, with retailers in the UK pausing sales, could potential consumers eyeing the Satio for a holiday purchase look elsewhere? It seems likely.

    This also casts a dark cloud on the Satio’s release in the USA, if it ever comes this way.

    Sony Ericsson said it was “giving this matter its utmost priority and working toward solving it”.

  • REPORT: Mitsubishi considering gasoline-engine MiEV

    Filed under: , ,

    Mitsubishi i MiEV – Click above for high-res image gallery

    Mitsubishi already plans on selling its little MiEV electric car in the U.S. within the next 18 months, and it appears that we may get a gasoline powered version of the roomy micro car as well. Automotive News is reporting that Mitsubishi is mulling the idea of putting petrol power in charge of propulsion of some i models, giving dealers a higher volume line that can compete with the Smart Fortwo. The automaker already sells a gasoline powered i in Europe, but Mitsubishi Motors North America VP John Koenig reportedly told AN that the Euro model’s turbocharged 660cc motor would likely be swapped out for the same Mitsubishi-sourced 1.0-liter three-cylinder model that powers the Smart.

    If Koenig wants to bring the gas-powered i to the States, he estimates that he’ll have to prove that dealers can sell 1,000 models per month in order to get the parent company to pull the trigger. That sounds doable to us considering Smart sold 20,000 Fortwo’s in the first 10 months of production – in spite of the fact that the unique-looking micro mini is premium-priced and only has two seats. The i can comfortably seat four and it can probably be sold for close to the Fortwo’s $11,990 starting price. The typical i sells in more small car tolerant Europe for $16,000.

    [Source: Automotive News – subs. req.]

    REPORT: Mitsubishi considering gasoline-engine MiEV originally appeared on Autoblog on Tue, 24 Nov 2009 17:57:00 EST. Please see our terms for use of feeds.

    Read | Permalink | Email this | Comments

  • Calves Training Tips

    Calve Muscle Anatomy There are two primary muscle groups on the back of the lower legs – the gastrocnemius and the soleus muscles. The soleus is a wide, flat muscle that lies beneath the heart shaped gastrocnemius. Both muscles contract to extend the feet and toes, but the soleus can only fully contract when your leg is bent to at least a 30-degree angle. There are several other smaller muscles in your lower legs, all of which will be developed by focusing on working the calves. The only exception is the tibialis anterior muscle, which runs up the front of your shin and contracts to pull your foot and toes upward. If you have trouble developing your calves you can work these muscles more frequently then other muscle groups. They are tough, dense muscles and they can handle a bigger workload. Calve Exercises It is essential that when you do any exercise that you perform the movements correctly, if you don’t you will receive less then optimum benefit from the exercise. It is very difficult to unlearn bad exercise habits, so it is best to learn the right exercise technique from the very start. For each calve workout do 4 sets for each exercise listed below. One workout do high reps (i.e. 15+ per set) the next workout do low reps (i.e. 5-10 per set). This is one of the best ways to get stubborn calve muscles to grow. Standing Calve Raise This is a basic calve movement that works the gastrocnemius muscles. Step up on the foot block of the machine and place your head between the shoulder pads. Position yourself so that your shoulders are comfortably under the pads. Place the balls of your feet on the foot block, with your feet about shoulder width apart, toes pointing forward. Straighten your legs and support the weight on your shoulders. Keep your knees straight during the entire movement. Slowly lower your heels until your calve muscles stretch down as far as possible. Hold the stretched position for a second and then rise up as high as you can on your tippy toes. Hold this position for a second to enhance the peak contraction in the calves. Repeat. Tip – for a variation you can do this exercise with one leg at a time. If you do not have access to a standing calve raise you can perform the exercise with a barbell across your shoulders instead. Seated Calve Raise This exercise targets the soleus muscles because it is performed with your legs bent at a 90-degree angle. This exercise also works the gastrocnemius muscles are as secondary muscles. Adjust the knee pads of the machine so that you can sit with your knees snug to the pads. Place the balls of your feet on the foot block, with your feet about shoulder width apart, toes pointing forward. Rise up as high as you can on your tippy toes. Hold this position for a second to enhance the peak contraction in the calves. Slowly lower your heels until your calve muscles stretch down as far as possible. Hold the stretched position for a second. Repeat. Tip – if you do not have access to a seated calve raise machine you can do this exercise seated on the end of a bench with a barbell wrapped in a thick towel placed on top you’re your knees. Donkey Calve Raises This different looking exercise is excellent for working the gastrocnemius muscles. Secondary stress is applied to the soleus muscles. Stand with the balls of your feet on a block, with your feet about shoulder width apart, toes pointing forward. Bend over and rest your hands on an exercise bench so that your upper body is parallel to the floor while keeping your legs straight. Have a training partner sit up on your hips and balance in place as if they were riding a horse. Slowly lower your heels until your calve muscles stretch down as far as possible. Hold the stretched position for a second. Rise up as high as you can on your tippy toes. Hold this position for a second to enhance the peak contraction in the calves. Repeat. 1 Leg Calve Raise This exercise works the gastrocnemius muscles. Note: This pic shows a 2 leg calve raise, you can also do them one leg at a time. Stand on one leg with the ball of your foot on a calve block and your heels hanging off the edge of the block. You should hold onto something, such as a squat rack, to help you keep your balance. Keep your knee straight during the entire movement. Slowly lower your heel until your calve muscle stretches down as far as possible. Hold the stretched position for a second and then rise up as high as you can on your tippy toes. Hold this position for a second to enhance the peak contraction in the calve muscle. Repeat for the desired number of reps. Repeat with the other leg. Tip – you can hold a dumbbell or do this exercise in a standing calve raise machine to add more resistance. This is a good exercise to do as a warm up or as a finishing exercise for your calve workout.

  • November 2009 Medical Journal Article Describes Large Ongoing Study About Safety Of YAZ

    INAS-OC Study: Intended To Evaluate Risk Of Developing Cardiovascular Side Effects For Women Who Use YAZ (DRSP/EE 24d)

    (Posted by Tom Lamb at DrugInjuryWatch.com)

    In May 2009 we first wrote about the International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study), which is intended to evaluate the risk of developing cardiovascular side effects for women who use YAZ, a popular birth control containing a unique progestin, drospirenone (DRSP), and a relatively low dose of an estrogen, ethinylestradiol (EE).  We reported, then, that this YAZ safety study had started in August 2005 and was ongoing as of May 2009.

    We recently learned more about the current status of this INAS-OC Study in an article published November 18, 2009 by BMC Medical Research Methodology— which is an open access journal publishing original peer-reviewed research articles in methodological approaches to healthcare research.

    The November 2009 medical journal article about this ongoing YAZ safety study is called “International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study)”.

    From the Abstract for this INAS-Study article we get this information:

    BACKGROUND: A 24-day regimen of contraceptive doses of drospirenone and ethinylestradiol (DRSP/EE 24d) was recently launched. This regimen has properties which may be beneficial for certain user populations (e.g., women suffering from premenstrual dysphoric disorder or acne). However, it is unknown whether this extended regimen has an impact on the cardiovascular risk associated with the use of oral contraceptives (OCs). The INternational Active Surveillance study of women taking Oral Contraceptives (INAS-OC) is designed to investigate the short- and long-term safety of the new regimen in a population which is representative for the typical user of oral contraceptives. Methods / Design A large, prospective, controlled, non-interventional, long-term cohort study with active surveillance of the study participants has been chosen to ensure reliable and valid results. More than 2,000 gynecologists in the US and 5 European countries (Austria, Germany, Italy, Poland, and Sweden) will recruit more than 80,000 OC users. The two to five year follow-up of these women will result in at least 220,000 documented women-years. The main clinical outcomes of interest for the follow-up are deep venous thrombosis, pulmonary embolism, acute myocardial infarction and cerebrovascular accidents….

    We look forward to eventually seeing the results obtained from this INAS-OC Study, which is reportedly funded by an unconditional grant from Bayer Schering Pharma AG, Berlin.

    ______________________________________________________________________________

    DrugInjuryLaw.com: Legal Information And News About Prescription Drug Side Effects












  • Toyota extends Tundra rust recall to include 2000-03 models, totalling 110,000 trucks

    Filed under: , , ,

    If you’ve been following the Toyota Tundra rust saga, you’re aware that NHSTA recently requested data from Toyota about the purported frame corrosion affecting 2000 and 2001 models. Today, Toyota has extended that recall to include the 2002-03 model years, saying that a small number of trucks could suffer from frame corrosion that could cause the spare tire to detach from its underbody housing. That brings the total up to 110,000 Tundras located in 20 cold-weather states and the District of Columbia.

    Toyota will begin an inspection program next month which will run through January of 2010, and if you’re driving one of the affected pickups, you can get all the details in the press release below the fold. Hat tip to Mike from Pickuptrucks.com.

    Continue reading Toyota extends Tundra rust recall to include 2000-03 models, totalling 110,000 trucks

    Toyota extends Tundra rust recall to include 2000-03 models, totalling 110,000 trucks originally appeared on Autoblog on Tue, 24 Nov 2009 17:27:00 EST. Please see our terms for use of feeds.

    Permalink | Email this | Comments

  • Bank Of America Bulls Snap Up Call Options

    bank of america

    Shares of Bank of America were down slightly today but activity in the options market indicates that long-term bulls are unshaken.

    Could this be a play on the possible nomination of a new CEO tomorrow?

    Phil of Phil’s Stock World (incidentally, one of the best options blogs around) reports:

    Long-term Bank of America bulls are out in full force today, scooping up call options like they’re going out of style. BAC’s shares are off slightly by less than 1% to $16.19.

    Plain-vanilla call buying in the January 2011 contract indicates investors expect shares to surge over the next 13 months. A large chunk of 50,000 calls were picked up at the January 25 strike for an average premium of 86 cents apiece. Shares must rally 60% from the current price to breach the $25.86 breakeven point on the trade. Twice as many calls were coveted at the higher January 30 strike where 100,000 calls were purchased for 45 cents each. The investor responsible for the massive position breaks even if shares jump 88% to $30.45 by expiration.

    Finally, another BAC-optimist established a ratio call spread in the same contract. The investor purchased 20,000 calls at the January 20 strike for 1.95 apiece, spread against the sale of 40,000 calls at the higher January 30 strike for 46 cents premium each. The net cost of the spread amounts to 1.03 per contract and positions the trader to profit if shares exceed $21.03 by expiration in January of 2011. Maximum potential profits available on the transaction amount to 8.97 per contract.

    Option implied volatility on Bank of America is currently 38.65% – a scant 2.93% above the 52-week volatility low of 35.77% – attained back on October 20, 2009.

    Click here for Phil’s other reports on GE and the seed market.

    Join the conversation about this story »

    See Also:

  • Big Deal? VW racing chief, F1 drivers visit Homestead for NASCAR season-closer

    Filed under: ,

    This year’s Sprint Cup was awarded this past weekend at Homestead, where Jimmie Johnson scored his record fourth consecutive championship with a fifth-place finish behind race winner Denny Hamlin. (Oh yeah, “spoiler alert”.) Anyway, on to the interesting part: the oval speedway had some unlikely German visitors for the series finale, leading the motorsport press and the fans to begin asking questions.

    The Volkswagen Group’s head of motorsports Hans-Joachim Stuck was reportedly among the spectators at Homestead this past weekend, and took a few visible meetings with NASCAR officials. But Stuck was quick to dispel any rumors. Although he kvelled over the purity of the spectacle that NASCAR offers, Stuck said that convincing the bean counters back in Wolfsburg that stock car racing made sense for them would be a tough sell.

    If you think it would be an even tougher sell to fans, consider that VW’s new plant in Chatanooga, Tennessee, could be only the first step in an increasing American presence for the German automaker, and that Toyota may have already prepared the ground for foreign makes to enter the series.

    Meanwhile Stuck did confirm ongoing negotiations over the German auto group’s potential participation in the Grand Am sportscar series, also owned by NASCAR’s France family. According to Stuck, the Audi/Lamborghini V10 could be a perfect fit for the prototype racers, though they’d have to make it work with the spec ECU. Stuck also revealed that his company was discussing a possible entry into the IndyCar series.

    The VW racing chief wasn’t the only notable German at Homestead this past weekend, though, as Red Bull flew out its star driver Sebastian Vettel to witness the spectacle as well. After watching the race and chatting with former colleague Juan Pablo Montoya, Vettel said that F1 could stand to learn a lot from NASCAR, and that while he’s committed to F1, he’d like to try out a stock car on an oval. This after his professed fascination with rallying as well. It’s worth noting that Heikki Kovalainen, now looking for a new drive since leaving McLaren, was also at the race as a guest of Penske Racing, leading to speculation over the Finnish driver’s prospects for next season.

    [Source: Autosport | Image: Jason Smith/Getty]

    Big Deal? VW racing chief, F1 drivers visit Homestead for NASCAR season-closer originally appeared on Autoblog on Tue, 24 Nov 2009 16:59:00 EST. Please see our terms for use of feeds.

    Read | Permalink | Email this | Comments

  • Jury Says Fictional Character Can Be Libelous

    Plenty of fiction authors base their characters on real life people. But, perhaps they need to be more careful. A jury has ruled in favor of someone who claimed libel against an author for supposedly writing a character “inspired by” a former friend. That former friend was not happy about the portrayal, in which she was a “sexually promiscuous alcoholic.” This seems like a really bad precedent. Fiction authors quite frequently take people from real life, but then exaggerate them to extremes. But if that opens them up to potential libel charges, that seems quite ridiculous.

    For example, I once read a book that had a character that was based on my father, written by someone who knew him many, many years ago (in the copy the author sent my father, it was inscribed with my father’s name, followed by the character’s name in parentheses). It was entertaining, to me, to see such a character who certainly resembled the rather content, laid back, unflappable nature of my Dad… except at the end where the character went crazy and had to be locked up. That, clearly, did not happen in real life, but it never struck me as “libelous.” It was obviously just a fictional story, where the author needed the character to do something and act in a certain way. That’s why it’s fiction. Besides, for it to be defamatory, you have to be able to show the harm caused, and that’s only going to happen if a lot of people know that the character is supposed to be the real person, which seems unlikely in most cases. In the meantime, though, if you’re writing a fictional story, be careful who you base your characters on.

    Permalink | Comments | Email This Story





  • Review: Research Report on Pain and Depression in Older People

    The paper reviewed here is ‘Pain and Depression in Older People: Comorbidity and Patterns of Help Seeking’ by Bonnewyn and colleagues. In the conclusion to the abstract the authors write that

    (Painful physical symptoms) were more likely in people with a 12-month major depressive episode (MDE) than in those without (OR=2.0)

    In the introduction, the authors cite research showing a prevalence of pain in older adults of between 25 and 88%. The authors then briefly discuss the pain-depression dyad explaining the antecedent and consequence hypotheses which expand on the nature of the dyad. The aims of the study are clearly outlined and include an evaluation of the relationship between pain and depression in a community-dwelling sample of older adults (65 years and older) as well as the interactions with the use of mental health services and benzodiazepine use.

    The data was obtained from the European Study on the Epidemiology of Mental Disorders (ESEMeD) a study which was initiated by the World Health Organisation. Data was obtained from 6 countries – France, Germany, Italy, Belgium, Holland and Spain. The researchers write that some of the specifics of the sampling process have been described in another paper. I wasn’t clear on the details of the sampling method as a result and the researchers note that

    a stratified, multistage, clustered area, probability sample was used

    59.4% of the sample were female and 38.4% were age 75 and over. 36.3% of the sample lived in rural areas compared to 26.6% that lived in urban areas. The majority of the sample (52%) had 0-11 years of education. Participants were interviewed using the Composite International Diagnostic Interview with major depressive disorder diagnosed using DSM-IV criteria and a list of questions used to detect the presence of painful symptoms specifying within the last 12 months in some of these questions. They were also asked if they had one of a number of chronic medical conditions some of which are common medical conditiosn (e.g. asthma and diabetes). They were also asked about antidepressant and benzodiazepine use. Their estimated point prevalence of painful physical symptoms in the sample was 31.8% and although they were calculated as more common in men there was no confidence intervals for this comparison. PPS were significantly more likely in females with major depressive episode than those without. Using depression as the dependent variable, the researchers ran a multvariate analysis which identified female gender and pain as predictors of depression. Without major depression, the likelihood of antidepressant use was three times greater in those with painful physical symptoms compared to those without. For participants with depression, there was no significant difference between those with and without painful physical symptoms in the use of antidepressant medication. There was a doubling in the use of benzodiazepines in those without major depression but with painful physical symptoms (PPS) compared to those with major depression but without PPS. Major depression was also found to be signficantly associated with benzodiazepine use.

    In the discussion, the authors note that from their results somatic conditions mediated the relationship between depression and pain. The authors also  comment on the two-fold increase in PPS with major depressive episode and the increased prevalence of PPS with female gender. Whilst these latter two findings were consistent with previous literature, like the researchers I found the results for antidepressant and benzodiazepine use interesting. Firstly antidepressant use was found to be higher in those without major depression but with pain. The use of benzodiazepines was increased in those with major depression also. I wasn’t clear if there was a prominent anxiety component in those using benzodiazepines but given that only 20% of those with depression were receiving antidepressants a different pattern of prescribing could be explored. This however would depend on local guidelines particularly as the sample is taken from 6 countries.

    In conclusion, I thought there were some interesting findings here particularly the use of antidepressants in those with pain but not major depression. It could be that the depression had been previously treated and was in remission. Alternatively it could mean that the subject or the prescriber had intended for the antidepressants to be used for the pain. It would be interesting to see how factors such as pain duration and intensity impact on antidepressant use. The paper provides valuable insights into the relationship between pain and depression in older adults and I would be interested to see in particular if there are any follow-up studies examining the use or underprescribing of antidepressants as well as benzodiazepine in the same or other regions.

    References

    Bonnewyn A, Katona C, Bruffaerts R, Haro J M, de Graaf R, Alonso J and Demyttenaere K. Pain and Depression in Older People: Comorbidity and Patterns of Help Seeking. Journal of Affective Disorders. 117. 193-196. 2009.

    Twitter

    You can follow ‘The Amazing World of Psychiatry’ Twitter by clicking on this link

    Podcast

    You can listen to this post on Odiogo by clicking on this link (there may be a small delay between publishing of the blog article and the availability of the podcast).

    TAWOP Channel

    You can follow the TAWOP Channel on YouTube by clicking on this link

    Responses

    If you have any comments, you can leave them below or alternatively e-mail [email protected]

    Disclaimer

    The comments made here represent the opinions of the author and do not represent the profession or any body/organisation. The comments made here are not meant as a source of medical advice and those seeking medical advice are advised to consult with their own doctor. The author is not responsible for the contents of any external sites that are linked to in this blog.

  • How We Are Smart by W. Nikola-Lisa, illustrated by Sean Qualls

    Using research originally developed by Harvard psychologist Dr. Howard Gardner about multiple intelligences which was made popular by Dr. Thomas Armstrong, author Nikola-Lisa chooses 12 achievers to show how they were each ’smart’ in different, important ways. “Here are eight basic ways people can be smart,” Nikola-Lisa writes in his introduction using Armstrong’s terms: body smart, logic smart, music smart, nature smart, people smart, picture smart, self smart, and word smart.

    Each eye-catching double-page spread begins with a quote from the subject, a poem that highlights his or her accomplishments, and ends with a short biography. Parents: sharing this title with your younger readers is highly recommended – you might find yourself amazed at how much history we missed (or had missed for us) given most of our Eurocentric educational pasts!

    From Spanish Irish physicist Luis Alvarez to Native American Scotch Irish prima ballerina Maria Tallchief to Japanese American Congresswoman Patsy Takemoto Mink to African American explorer Matthew Henson to Mexican American botanist Ynés Mexía, Nikola-Lisa admirably chooses a variety of backgrounds both professionally and culturally to illustrate the very diversity of how “each person [is] an individual blend of several intelligences.”

    And since the title is How We Art Smart, Nikola-Lisa finds ways in which the young reader can get involved: “Now it’s time for you to think / about the ways we are smart …” Activities, further reading, a myriad of resources provide ample opportunities for further exploration and discussion … every book should have such a rich and continuous afterlife!

    Readers: Children

    Published: 2006, 2009 (paperback re-issue)